Skip to content
Screener

Alkermes ALKS Total Liabilities

Total Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$65.32B-15.4%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$659.02M+21.3%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$1.34B-19.2%
LBR
LB Pharmaceuticals IncLBRX
$14.79M
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$361.48M+7.9%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.55B+8.6%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemJune 30, 2026December 31, 2025
LONG-TERM DEBT1,476,611
DEFERRED TAX LIABILITIES179,575
OTHER LONG-TERM LIABILITIES68,01861,008
Total liabilities2,584,575667,698
COMMITMENTS AND CONTINGENT LIABILITIES (Note 18)
SHAREHOLDERS’ EQUITY:
Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; and zero issued and outstanding at June 30, 2026 and December 31, 2025, respectively.
Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 184,700,718 and 181,011,166 shares issued; and 167,541,198 and 165,607,028 shares outstanding at June 30, 2026 and December 31, 2025, respectively1,8471,810

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's total liabilities?
Alkermes (ALKS) reported total liabilities of $2.58B in Q2 2026.
How has Alkermes's total liabilities changed year-over-year?
Alkermes's total liabilities increased by 311.4% year-over-year, from $628.23M to $2.58B.
What is the long-term trend for Alkermes's total liabilities?
Over 5 years (2020 to 2025), Alkermes's total liabilities has grown at a -5.4% compound annual growth rate (CAGR), from $882.75M to $667.7M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Alkermes's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude